Short Interest in UCB SA (OTCMKTS:UCBJY) Rises By 133.3%

UCB SA (OTCMKTS:UCBJY) was the target of a significant growth in short interest in September. As of September 30th, there was short interest totalling 700 shares, a growth of 133.3% from the September 15th total of 300 shares. Based on an average trading volume of 11,300 shares, the short-interest ratio is currently 0.1 days.

UCB Trading Up 1.9 %

UCB stock opened at $93.41 on Friday. The firm has a 50 day simple moving average of $88.99 and a 200-day simple moving average of $76.98. UCB has a 12-month low of $34.85 and a 12-month high of $94.16.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.